Cardlytics (CDLX) Current Deferred Revenue (2017 - 2026)

Cardlytics has reported Current Deferred Revenue for 10 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 4.98% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (up 4.98% YoY), and the FY2025 full-year result was $2.5 million, up 17.97% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $2.7 million, up from $2.5 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $4.7 million in Q2 2022, with the low at $1.5 million in Q1 2022.
• Historically, Current Deferred Revenue has averaged $2.6 million across 5 years, with a median of $2.6 million in 2025.
• The largest YoY upside for Current Deferred Revenue was 466.41% in 2022 against a maximum downside of 46.62% in 2022.
• Cardlytics' Current Deferred Revenue stood at $1.8 million in 2022, then soared by 37.35% to $2.4 million in 2023, then declined by 10.44% to $2.2 million in 2024, then advanced by 17.97% to $2.5 million in 2025, then rose by 7.75% to $2.7 million in 2026.
• The last three Current Deferred Revenue figures came in at $2.7 million (Q1 2026), $2.5 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.